An overnight switch to ropinirole therapy in patients with Parkinson's disease

M. Canesi, A. Antonini, C. B. Mariani, S. Tesei, A. L. Zecchinelli, M. Barichella, G. Pezzoli

Research output: Contribution to journalArticlepeer-review


Patients with Parkinson's disease (n = 68) switched from pergolide or bromocriptine to ropinirole overnight (dose equivalence ratios - 1:6 and 10:6, respectively). The activities of daily living score for the Unified Parkinson's Disease Rating Scale (UPDRS) was significantly improved 4 weeks after the bromocriptine-ropinirole switch. All other UPDRS scores, including that for the side-effect component, were not significantly different after either switch. Overnight switching may be a safe therapeutic approach that may reduce hospitalisation and related socio-economic costs.

Original languageEnglish
Pages (from-to)925-929
Number of pages5
JournalJournal of Neural Transmission
Issue number9-10
Publication statusPublished - 1999


  • Bromocriptine
  • Parkinson's disease
  • Pergolide
  • Ropinirole

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'An overnight switch to ropinirole therapy in patients with Parkinson's disease'. Together they form a unique fingerprint.

Cite this